Sepsis is a Complex and Challenging Condition to Manage for Medical Teams with 3 Main Challenges
- Non-exclusive symptoms
Making sepsis difficult to recognize among other conditions, but accurate population-level data remains elusive. - Unavailable or delayed information1,2
With an average of 3 days to a complete analysis from blood culture, increasing risk of inadequate therapy or overtreatment - Complex process from multidisciplinary teams
Establish effective collaboration with nurses, pharmacists, laboratories staff, etc.
The longer it takes to administer the right treatment, the lower the survival rate3
+
Clinicians must initiate antimicrobial therapy as early as possible
≈
20-30% of patients receive inappropriate therapy4,5,6
BURDEN OF SEPSIS
Every hour of delay in giving appropriate antibiotics increases
MORTALITY BY 9%3
Every
2.8 SECONDS
someone dies from sepsis8
> 40% OF ALL CASES
occur in children under 57
1 IN 3 PEOPLE
who die in a hospital had sepsis during that hospitalization3
$62B
estimated annual cost for US hospitalizations8
1.7M
cases of sepsis among US adults each year3
Although any infection can lead to sepsis
OVER 40% OF PATIENTS WITH A BLOODSTREAM INFECTION DEVELOP SEPSIS
and over 15% go on to develop septic shock.6
Blood culture remains the gold standard for diagnosing sepsis.9,10
80% OF SEPSIS DEATHS COULD BE PREVENTED
by quicker diagnosis and treatment11
bioMérieux is your partner of choice for sepsis management. Impact patient outcomes for sepsis and experience key benefits for your institution.
Using a diagnostic technique to manage BSI early provides
Reduced mortality12,13
Reduced length of stay, readmission rate, and complications14
Decreased broad-spectrum antibiotic consumption and associated costs15
Efficient monitoring of nosocomial infections and MDRO
A Worrisome Link: Sepsis and Antimicrobial Resistanc
Antimicrobial resistance is a key concern in cases of sepsis.
Empirical therapy typically implemented prior to diagnostics driven therapy optimization carries risks for unnecessary broad spectrum treatment or incorrect treatment, which are associated with increased potential for development of antimicrobial resistance.
Sepsis patients with infections caused by resistant organisms are the most difficult to treat and have the highest risk of mortality16.
As more resistant bacteria emerge, the arsenal of effective antibiotic treatments for sepsis is reduced
Empower your lab, clinicians and institution for enhanced sepsis management with automated solutions for workflow efficiency.
And when you re ready for more, it s easy with bioMérieux's fast integrated SEPSIS SOLUTION
"
"Progress in BSI pathogen diagnostics is based on a bundle approach that includes optimization of the pre-analytical parameters, rapid start of incubation, the use of rapid methods, re-organization (e.g. 24/7, transportation service) and a close involvement of antimicrobial stewardship teams. These developments lead to define a new standard for bloodstream infection diagnostics.”17
Benefits of the Bundled Approach Based on 3 Main Recommendations
IMPROVE SAMPLE QUALITY
Reduce contamination Increase volume of blood collected
Reduce Analytical Time
Fast identification (ID) Fast Antimicrobial Susceptibility Testing (AST) Operating 24/7
REDUCE PRE- & POST-ANALYTICAL TIME
Streamline logistics Optimize treatment Operating 24/7
Enable results within 24 hours*
How can bioMérieux’s fast, integrated SEPSIS SOLUTION enable bloodstream infection diagnostic results in just 24 hours, compared to 60 hours or more with traditional methods?
BACT/ALERT® VIRTUO®
Detects 8.7 hours earlier in aerobic blood culture bottles from patients already on patients already on antimicrobial treatment18
BIOFIRE® BCID2 Panel
Provides identification (ID) and antimicrobial resistance (AMR) genes results in ~1 hour, decreasing the time to optimal therapy19, 20, 21, 22
VITEK® REVEAL™
Enables fast targeted therapy with phenotypic antimicrobial susceptibility testing (AST) results in an average of 5.5 6h, 18h earlier than traditional AST for blood culture23, 24, 25, 26
MAESTRIA™ / CLARION™
Integrate diagnostics results and transform your data into relevant actionable healthcare insights
Empower your lab, clinicians and institution with a fast, integrated approach to sepsis management.
Start Optimizing Your Sepsis Workflow
2 Sweeney TE et al. Expert Review of Molecular Diagnostics 201_, ~OL. 1_, NO. 11, _5_–_62
3 Liu ~X et al., American Journal of Respiratory and Critical Care Medicine, 2017
4 Schuttevaer R, et al. PLoS One, 201
5 Baltas I, et al. J Antimicrob Chemother. 2021
6 Kadri SS, et al. The Lancet Infectious Diseases, 2021
7 Pfuntner A et al., HCUP Stat Brief, 201
8 Rudd E, The Lancet Infectious Diseases, 2020
9 Duncan CF et al., Curr Infect Dis Rep, 2021
10 Sinha M et al., Clin Microbiol Rev, 2018
11 Sepsis Alliance. Sepsis fact sheet, 2022
12 Timbrook et al., Clinical Infectious Diseases, 2016
13 Senok A, et al., Diagnostics, 2023
14 De La villa et al. Journal of Antimicrobial Chemotherapy, 2023
15 Britt NS, et al. Pharmacotherapy, 2023
16 Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis 3). JAMA 2016; 315:801-810
17 Lamy B., et al.: “Bloodstream infections Standard and progress in pathogen diagnostics . Clin Microbiol Infect. 2020 Feb; 26
18 Halperin A, et al. Microbiology spectrum vol. 10,5 (2022)
19 Chiasson J, et al. J Pharm Prac. 2021; 35(5):722 72
20 Verroken A., et al. (201_). PLOS ONE: 14(_): e0223122
21 Mac~ane S and Note F. J Clin Microbiol. 2016 Oct;54(10):2455 63.
22 Banerjee R et al. Clin Infect Dis 2015;61:1071-80.
23 Rottman M, et al. ECCMID 2022.
24 BMX. 1. 12_8__ Clinical Trial Summary Report (proprietary, on file at bioMérieux).
25 Yuceel Timur I, et al. ECCMID 2023
26 Gastli N, et al. ECCMID 2023
*The 24 hour window for results is a calculated value based on instrument run time.